News Oncolys BioPharma Inc.

Equities

4588

JP3202170001

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
698 ^JPY	+1.75%		+4.49%	+23.10%

Feb. 09	Oncolys BioPharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 07	Medigen Biotechnology Corp. Announces Signing of the Sales Cooperation Agreement for the New Drug OBP-301 in Japan	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oncolys BioPharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 09	CI
Medigen Biotechnology Corp. Announces Signing of the Sales Cooperation Agreement for the New Drug OBP-301 in Japan	Feb. 07	CI
Oncolys BioPharma : Announcement of Investigator-Initiated Phase 2 Clinical Trial Agreement For Immunotherapy refractory Esophagogastric adenocarcinoma	Dec. 19	PU
Oncolys Biopharma Inc. Announces the Investigator-Initiated Phase 2 Clinical Trial Agreement with Weill Cornell Medicine	Dec. 19	CI
Oncolys Biopharma Inc. Provides Update on Phase II Study of Telomelysin (OBP-301) in Combination with Pembrolizumab in Gastroesophageal Adenocarcinoma	Nov. 07	CI
Oncolys Biopharma Announces Enrollment of First Expansion Cohort Patient in Phase I Clinical Trial for Telomelysin (OBP-301)-Chemoradiation Combination Therapy	Nov. 02	CI
Oncolys BioPharma : Achievement of Primary Endpoint for Efficacy in the Phase2 Clinical Trial for Telomelysin-Radiation Combination Therapy	23-10-16	PU
Oncolys BioPharma Inc. Announces Achievement of Primary Endpoint for Efficacy in the Phase2 Clinical Trial for Telomelysin-Radiation Combination Therapy	23-10-16	CI
Oncolys Biopharma Announces Meeting of Safety Endpoint in the Initial Safety Cohort of the Phase I Clinical Trial for Telomelysin?? in Combination Therapy	23-08-10	CI
Oncolys BioPharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-04	CI
Oncolys Biopharma Partner Enrolls First Patient in Phase IIa Study of Aicardi-Goutières Syndrome Drug	23-07-26	MT
Oncolys Biopharma Inc. Announces Enrollment of First Patient in Phase Iia Study for Obp-601 in Patients with Aicardi-Goutieres Syndrome	23-07-25	CI
Oncolys BioPharma Inc. announced that it has received ¥21.106 million in funding from SMBC Nikko Securities Inc., Investment Arm	23-07-23	CI
Oncolys BioPharma Inc. announced that it expects to receive ¥21.106 million in funding from SMBC Nikko Securities Inc., Investment Arm	23-07-06	CI
ASCO 2023 ANNOUNCEMENT: Encouraging Preliminary Data of OBP-301 with Pembrolizumab in refractory gastroesophageal adenocarcinoma	23-06-06	PU
Oncolys BioPharma Announces Results from an Investigator-Initiated Phase II Clinical Trial for Telomelysin™? (OBP-301) in Combination with Pembrolizumab in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma	23-06-06	CI
Oncolys BioPharma : Non-consolidated Financial Results for the Three Months Ended March 31, 2023	23-05-12	PU
Oncolys BioPharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Oncolys BioPharma Inc. Announces Completion of Enrollment in Phase IIa Clinical Trial of OBP-601 (censavudine, TPN-101) in Patients with Amyotrophic Lateral Sclerosis	23-03-07	CI
Oncolys BioPharma : Non-consolidated Financial Results for the Nine Months Ended September 30, 2022	22-11-04	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Oncolys BioPharma Inc.

Equities

4588

JP3202170001

Summary

Filters